In addition, I opposed the bill because it inexplicably delays the Trump Administration's Medicare Part D rebate rule, which would have ensured that drug rebates are directed to patients rather than to the pockets of Pharmacy Benefit Managers (PBMs) who are responsible for negotiating drug prices between insurance companies and pharmacies.